Fort Washington Investment Advisors Inc. OH Purchases 695,740 Shares of Progyny, Inc. (NASDAQ:PGNY)

Fort Washington Investment Advisors Inc. OH raised its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 90.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,467,780 shares of the company's stock after acquiring an additional 695,740 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 1.72% of Progyny worth $25,319,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Quarry LP grew its stake in shares of Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company's stock worth $25,000 after purchasing an additional 836 shares during the period. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Progyny in the 2nd quarter valued at approximately $44,000. Mendota Financial Group LLC bought a new position in Progyny during the 3rd quarter worth approximately $56,000. Finally, Meeder Asset Management Inc. acquired a new position in Progyny during the third quarter valued at approximately $77,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Activity

In other Progyny news, CEO Peter Anevski bought 209,500 shares of the firm's stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the transaction, the chief executive officer now directly owns 441,463 shares in the company, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the acquisition, the chairman now directly owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Progyny Price Performance

PGNY stock traded up $0.87 during mid-day trading on Thursday, reaching $22.02. The company had a trading volume of 887,612 shares, compared to its average volume of 2,039,339. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.96, a PEG ratio of 2.15 and a beta of 1.31. The stock has a 50 day simple moving average of $16.40 and a two-hundred day simple moving average of $19.43.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same quarter in the prior year, the business posted $0.16 EPS. The business's quarterly revenue was up 2.0% compared to the same quarter last year. On average, equities analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Barclays reduced their price target on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Canaccord Genuity Group decreased their target price on Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. Bank of America dropped their price target on Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. Truist Financial reiterated a "hold" rating and issued a $19.00 price objective (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and set a $17.00 target price (down from $22.00) on shares of Progyny in a report on Monday, December 2nd. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Progyny presently has an average rating of "Hold" and a consensus target price of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.